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ABSTRACT 
Background: To measure uptake of first invitation to cervical screening by vaccine status in 
population based cohort offered HPV immunisation in a national catch-up campaign by 
vaccination status. 
Methods: A retrospective observational study of routinely collected data from the Scottish 
Cervical Screening Programme (SCSP). Data was extracted and linked from the Scottish 
Cervical Call Recall System (SCCRS), the Scottish Population Register and the Scottish 
Index of Multiple Deprivation. Records from 201,023 women born between 1st January 1988 
and 30th September 1993 were assessed. Women born in or after 1990 were eligible for the 
national catch-up programme of HPV immunisation. Attendance for screening was within 12 
months of first invitation at age 20 years. 
Results: There was a significant decline in overall attendance from the 1988 cohort to the 
1993 cohort with the adjusted odds of the 1988 cohort being 2.15 times (95% CI 2.07- 2.24) 
that of the 1993 cohort.  Immunisation compensated for this decrease in uptake with 
unvaccinated individuals having a reduced odds of attendance compared to those fully 
vaccinated (OR=0.42, 95% CI 0.41-0.43). Not taking up the opportunity for HPV 
immunisation was associated with an attendance for screening below the trend line for all 
women before the availability of HPV immunisation. 
Conclusion: HPV immunisation is not associated with the reduced attendance for screening 
that had been feared. Immunised women in the catch-up cohorts appear to be more motivated 
to attend than unimmunised women but this may be a result of a greater awareness of health 
issues. These results, whilst reassuring, may not be reproduced in routinely immunised 
women. Continued monitoring of attendance for first smear and subsequent routine smears is 
needed.  
  
INTRODUCTION 
Countries with organised cytology-based cervical screening programmes have shown a 
considerable decrease in the incidence of cervical cancer. Data from the UK and the Republic 
of Ireland demonstrate the temporal relationship between the central organisation of cervical 
screening in 1988 and the subsequent decrease in incidence of invasive cervical carcinoma 
(Comber & Gavin, 2004). In Scotland, women are currently screened between the ages of 20-
60. Uptake over 5.5 years for the years 2013 – 2014 was 77.3% overall, with 53.8% for those 
aged 20-24 (www.isdscotland.org/health-topics/cancer/cervicalscreening/). 
Uptake of cervical screening is affected by a number of factors, including deprivation, 
accessibility and acceptability of the test, educational attainment, and information about 
cervical cancer and hence perception of risk (Waller et al, 2009; Waller et al, 2012; Everett et 
al, 2012). Uptake is improved by a systematic approach to call and recall of women. There is 
a concern that women who have been vaccinated against HPV perceive themselves to be at 
low risk of developing cervical cancer and hence do not attend for screening when invited 
(Paynter et al, 2015; Price et al, 2011). Low uptake rates will make the screening programme 
increasingly ineffective, no matter which test is used and affect the benefits anticipated from 
vaccination. 
 
Continued attendance for cervical screening is important for many reasons. The HPV types 
employed in the two vaccines currently account for ~75% of cancers, depending upon the 
population. Cross-protection for HPV 31, 33 and 45 would increase the percentage of 
tumours potentially covered to between 75 and 80% (Smith et al, 2007; Cuschieri et al, 
2010). However, this leaves between 20 and 25% of tumours for which regular screening is 
still the only prevention. The duration of immunity is thought to be extensive on the basis of 
serological and population-based studies and there is emerging evidence of herd protection in 
countries with high uptake of vaccine (Cameron et al, 2016; Drolet et al, 2015; Tabrizi et al, 
2014). There are, however, still several areas which require to be elucidated including the 
effect of HPV immunisation at a population level in the long-term and possible HPV 
genotype replacement. Although preliminary population-based data suggests that type 
replacement may not be important clinically, at least in the short-term, there is thus a need for 
continued surveillance of both immunised and non-immunised women, for which adequate 
attendance at screening is required (Kavanagh et al, 2014). 
Scotland both screens from an early age (currently age 20) and has a highly organised and 
effective school-based immunisation programme. Uptake of vaccine in the catch-up cohorts 
(catch-up programme ran from September 2008 to end of 2011 and targeted girls aged 13-17) 
was 65% overall, varying between 40% in school leavers, to 80% in those still at school 
(ISD, 2012). Routine immunisation in school at age 12-13 continues to achieve greater than 
90% uptake of all three doses (ISD, 2014). In addition, Scotland has the advantage of direct 
linkage between immunisation status and cervical screening data through the use of a unique 
personal identifier, the Community Health Index (CHI) number that is used on all health care 
systems and records (Bhopal et al, 2012). It enables linkage of a wide variety of systems, 
allowing correlation of health interventions with disease and a variety of socio-economic and 
demographic factors. This enables direct examination of the effects of HPV immunisation on 
several aspects of service delivery. In this paper, we quantify the association between uptake 
of first invitation to cervical screening with uptake of HPV vaccination in the catch-up 
programme.  
METHODS 
Data selection and extraction 
The Scottish Cervical Call-Recall System (SCCRS) is a nation-wide, population register 
based computer system, populated with demographic data from the population register, in use 
since 2007 whose function is to manage all aspects of call and recall.  It incorporates 
immunisation status, acts as a requesting and reporting system for cytology and records 
relevant histology and HPV results. It includes in its reports recommended management and 
refers women directly for colposcopy. The dates of screening invitations and reminders are 
recorded, as are the reasons for exclusion from screening, for example pregnancy, no cervix, 
severe inter-current illness or a formal declaration to opt out. Invitations are sent to all 
eligible women at their current recorded address by GP registration. 
The screening attendance of all women born between 1st January 1988 and 30th September 
1993 in the year after their 20th birthday was obtained from SCCRS. This was based upon an 
extract in Q1 2015 which had validated data up to the end of Q3 2014.  Consequently, the 
1993 birth cohort is truncated to ensure this cohort has at least 12 months follow up.  The 
information included 
 date invited for screening, 
 date attended/reminded/defaulted as appropriate,  
 if excluded from screening, and reason for exclusion, 
 CHI 
 postcode of current residence recorded by registered general practitioner 
 number of doses of vaccine administered. 
Women in the dataset were classified as those eligible for the catch-up vaccination campaign 
and those not (those born before September 1990) according to their date of birth. 
Data Linkage 
The CHI registry dataset was used to identify the population in SCCRS that were resident in 
Scotland at age 20 and to eliminate any duplicate CHI records created in error, to record 
attendance for the same individual. Once duplicate records had been merged with retention of 
relevant data, women with legitimate exclusions were removed in order to obtain an accurate 
denominator for the eligible population. These exclusions included ’Not clinically 
appropriate’, death, transferred out of Scotland, and temporarily excluded for a co-morbidity 
or being pregnant.  
The postcode of residence was used to generate a deprivation code (Scottish Index of 
Multiple Deprivation SIMD 2012 version), and indices of rurality (Scottish Government 
Scottish Index of Multiple Deprivation http://www.scotland.gov.uk/Topics/Statistics/SIMD) 
Deprivation is divided into quintiles, with SIMD1 being the most deprived, and SIMD 5 
being the least deprived. Rurality is divided into three categories, urban (population of 
>10,000), accessible remote (30 – 60 minutes travel time from an urban centre, and very 
remote (>60 minutes travel time from an urban centre). Following data linkage, the data was 
anonymised by replacing the CHI number with a unique study number. 
Statistical analysis 
The influence of characteristics of 20 year old women on their likelihood of attending for 
screening was estimated through logistic regression, with a log link. The unadjusted and 
adjusted risk ratios of attendance by year of birth cohort, SIMD, number of vaccine doses (0-
3) and rurality were estimated. The primary data analysis was based upon all women resident 
in Scotland at age 20 and who were eligible for invitation to screening. We analysed 
attendance at screening over the subsequent 12 months so that all women had the same time 
opportunity to attend for screening.  In a secondary analysis, we investigated the effect of age 
on attendance for first screen by devising a time dependent analysis to properly account for 
the length of time that the earlier cohorts have to attend for screening compared to the 
younger cohorts.  The results from this analysis were indistinguishable for the primary one 
and so are not presented.  In a sensitivity analysis we analysed only those who were eleigible 
for vaccination, i.e. born after September 1990. 
Potential interactions between birth cohort and number of doses, and between number of 
doses and deprivation, on the uptake of screening were explored. As none of the interactions 
were pre-specified, we use a Bonferroni adjustment in model selection.  For the dose and 
deprivation interaction, further stratification was conducted to compare the uptake rates split 
by those eligible for the catch-up vaccination campaign and those not.  All statistical 
modelling was conducted in IBM SPSS Statistics version 15 (Chicago, USA) and graphics 
produced in Microsoft Excel. 
 
RESULTS 
Study population 
A total of 201,023 women were identified of whom 94,460 (47%) had attended for screening 
within 12 months of their 20th birthday. The demographic characteristics of all women are 
shown in Table 1. 
Uptake, Birth cohort, SIMD, immunisation and rurality 
Both unadjusted and adjusted analysis (Table 1) showed significant association between 
uptake and year of birth, SIMD, immunisation status and rurality (all p <0.05).There was a 
significant decline in overall attendance from the 1988 cohort to the 1993 cohort with the 
adjusted attendance ratio for those in the 1988 cohort being 1.49 times (95% CI 1.46-1.52) 
that of the 1993 cohort. Immunisation compensated for this decrease in uptake with 
unvaccinated individuals having a reduced ratio of attendance compared to those fully 
vaccinated (RR=0.65, 95% CI 0.64-0.65) (Table 1) but the downward trend with later birth 
cohorts persisted in those fully vaccinated (Figure 1). Attendance for screening decreased 
from baseline in the unvaccinated group after the introduction of immunisation compared 
with the 1988 and 1989 cohorts, who were almost all unimmunised, although there is a 
suggestion of a levelling off in those born in 1993.  Among those vaccinated, there is a clear 
trend of increased proportions attending with increasing number of doses, though in all 
groups there is a downward trend over time. 
The relationship between deprivation and screening attendance showed the lowest uptake in 
the least deprived individuals (Table 1) with statistically significant increased risk of 
attendance in all SIMD quintiles compared to the least deprived, although the scale of the 
increase is relatively small (adjusted RR~1.05 in all other SIMD groups).   
Interactions 
The most important interactions involved year of birth, SIMD and number of doses of 
vaccine, all with p< 0.001. There is an interaction between urban/rural status and SIMD (p = 
0.002), which is characterised by low screening attendance percentage for those in the least 
deprived groups in very remote areas.  The other interactions involving the urban/rural status 
were not important. 
Examination of the interaction between SIMD and vaccination status (Table 2) showed that 
unimmunised women in SIMD5 (least deprived) were also least likely to attend for screening. 
This was seen in all year of birth cohorts (Figure 2). Figure 2 also shows that the difference in 
uptake between the SIMD quintiles is widening in the younger cohorts of un-immunised 
women. Whereas women in SIMD1-4 born in 1998 and 1993 showed a trend of increasing 
attendance with decreasing deprivation, there was no consistent effect of SIMD on attendance 
from 1990 onwards. Uptake was however always lowest in the least deprived group (SIMD 
5). 
In those immunised during the catch-up vaccination campaign (Figure 3), full immunisation 
was associated with higher uptake of screening across all SIMD quintiles compared to partial 
immunisation. The deprivation differential is minimal among women who received 1, 2 or 3 
doses of the vaccine (Figure 3), with no clear trend discernible (p = 0.134). 
 
DISCUSSION 
Immunisation against HPV with the bivalent vaccine is associated with a higher uptake of the 
first smear at age twenty. The women subject to analysis had been eligible for the HPV 
vaccine as part of the catch-up cohort following the introduction of the HPV immunisation 
programme in Scotland, in September 2008. As the increased uptake was observed with any 
number of doses received, it may reflect characteristics of the women taking up the 
opportunity for immunisation, in particular their willingness to take responsibility for their 
own health. These results are encouraging for cervical screening of immunised populations in 
view of concerns of a hypothetical reduction in participation in screening and corroborate the 
effect previously reported from Wales (Beer et al, 2014). It is also consistent with the 
increased uptake reported in the United States and Sweden (Paynter et al, 2015; Sauer et al, 
2015; Herweijer et al, 2015). The intention to participate in screening reported in the United 
States, Australia and Scotland appears to have been realised (Price et al, 2011; Brotherton & 
Mullins, 2012; Paul-Ebhohimhen et al, 2010). 
Although immunisation is associated with an increased uptake of screening, the downward 
trend in uptake over the 6 year cohorts remains. This is worrying for screening as a process. 
Many factors affect uptake of cervical screening, including age, individual perception of risk 
and external influences, such as media coverage and celebrity involvement(Waller et al, 
2012; Moser et al, 2009). Deprivation is usually associated with decreased uptake of cervical 
screening, so the level of uptake in the least deprived quintile, observed in all unimmunised 
women, is both unexpected and unwelcome. The reasons for this are not clear but could relate 
to reduced usage of health services in this group of women when compared to the more 
deprived quintiles, or to population movements as a result of entering higher education or 
migration from areas with no linkage of immunisation to screening. Access to opportunistic 
screening is possible in Scotland, although minimal especially in young women with access 
to free health care. It has been a feature of Scottish cervical screening for some years. Ferris 
and colleagues report an intriguing observation that those who default from screening are 
more likely to take up immunisation because it will extend screening intervals (Ferris et al, 
2012). Whether, having taken up immunisation, the women then attend is not reported but 
our data would indicate that immunised women are more likely to attend for screening. 
Immunisation rates in the catch-up cohorts were related to deprivation, with a 5% reduction 
in vaccine uptake in the most deprived quintile compared to the least deprived (Sinka et al, 
2014). A similar trend in uptake of screening was not observed in the immunised cohorts, 
suggesting that being immunised has a more motivating effect on more deprived women than 
on more affluent women. Until there is a better understanding of the reasons for the poor 
uptake in the unimmunised and most affluent women, it is difficult to explain the relationship 
between uptake of screening to immunisation in this group. The uptake rates in unimmunised 
women are, however, strikingly low and this group should be the considered for further 
public health intervention. 
 
Close attention was paid to publicity about HPV immunisation and the relationship between 
HPV, cervical disease and screening during the immunisation campaign in 2008. The 
information given to young girls and their parents continues to stress the need for continued 
screening despite being immunised. The campaign was many-pronged, with advertisements 
on television and in cinemas as well as written information provided to the girls and their 
parents directly (Potts et al, 2013). The national screening leaflet for women invited for their 
first screening test has a section aimed at women who have been vaccinated to highlight the 
need for vaccinated women to attend for screening. This would appear to have been an 
effective strategy and suggests that, if appropriate information is given to women at the time 
of immunisation and when invited for screening, there is an appreciation that immunisation 
does not confer complete protection from cervical cancer and that screening is still necessary. 
However, from April 2016, the age at which young women will be screened in Scotland will 
increase to 25. Furthermore, in September 2014, the Joint Committee for Vaccination and 
Immunisation suggested that girls as young as 11 could be offered the HPV vaccine. 
Consequently, there will be a significant period of time (13 years) which will elapse between 
immunisation and invitation for first screen so it is critical that regular educational messages 
are communicated to young women in order to sustain the reduction in cervical disease. 
The strengths of this study are that it uses data routinely entered into SCCRS at a national 
level for the management of women in the Scottish Cervical Screening Programme. Results 
are entered contemporaneously and are available for any screening episode within Scotland. 
Data quality is actively managed through the programme. The CHI number allows direct and 
robust linkage of many aspects of an individual’s health record. The use of a national 
screening database means that the sample size is substantially larger than most previous 
studies. Although the Swedish study of Herweijer and colleagues was larger overall, there 
were significantly fewer immunised women (Herweijer et al, 2015). 
One of the main limitations of this study is that the women analysed may be a different 
population, with different motivation, from women immunised routinely at age 12/13. 
Paynter et al have reported that whilst uptake in recently immunised women is better than un-
immunised women of the same age, this effect diminishes as the time between immunisation 
and eligibility for cervical screening increases (Paynter et al, 2015). Although such a trend is 
not apparent in this analysis, these results may not be generalisable to all immunised 
populations. The analysis will therefore need to be repeated when routinely immunised 
women from the school based programme enter the Scottish Cervical Screening Programme 
from September 2015. Other limitations are that the observational nature of this study means 
we are unable to account for possible confounding due to variation in uptake of vaccination 
and of screening by factors such as school attendance, educational attainment, and 
employment. The very high uptake of immunisation in Scotland means that the numbers of 
partially immunised women are small, and thus the confidence limits for those women 
vaccinated with one and two doses are wide. Further work includes extending these 
observations to include routinely immunised women. Our results look only at first invitation 
to screening and it is important to examine attendance at second and subsequent routine 
screens. The comprehensive nature of the SCCRS database makes this eminently possible.  
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Table 1. Demographics of women born between 1st January 1988-September 1993 invited for screening. 
            
   
Univariate 
 
Multivariate 
 
Multivariate Eligible for routine HPV 
vaccination (born in 1990-onwards) 
 No. of 
women 
Attendance 
% 
Risk 
ratio 
Lower 
CI 
Upper 
CI 
Risk 
ratio 
Lower 
CI 
Upper 
CI Risk ratio Lower CI 
Upper 
CI 
Year of Birth 
    
   
  
  
  
    
1988 34,506 48.7 1.100 1.081 1.119 1.494 1.464 1.524   
 
  
1989 33,886 47.7 1.077 1.059 1.097 1.462 1.433 1.492   
 
  
1990 35,333 47.5 1.073 1.055 1.092 1.330 1.306 1.354 1.201 1.172 1.231 
1991 35,510 47.7 1.077 1.058 1.096 1.111 1.092 1.130 1.115 1.096 1.134 
1992 35,578 45.6 1.029 1.011 1.048 1.019 1.001 1.037 1.018 1.000 1.035 
1993 26,210 44.3 1 
  
1 
  
1     
Doses of Vaccine 
                      
0 128,629 43.6 0.807 0.799 0.815 0.645 0.637 0.654 .592 .582 .602 
1 3,285 44 0.815 0.784 0.848 0.791 0.761 0.822 .796 .765 .829 
2 6,343 48.1 0.891 0.868 0.915 0.863 0.841 0.886 .869 .845 .893 
3 62,766 54 1     1     1     
SIMD 
    
   
  
  
      
1 (Most Deprived) 45,007 46.4 1.038 1.023 1.054 1.040 1.025 1.055 1.039 1.019 1.060 
2 41,655 47.6 1.064 1.049 1.080 1.058 1.043 1.073 1.045 1.025 1.067 
3 38,969 47.5 1.062 1.047 1.078 1.049 1.034 1.065 1.034 1.013 1.056 
4 34,243 49.1 1.097 1.080 1.114 1.070 1.054 1.086 1.044 1.023 1.066 
5 (Least Deprived) 41,149 44.7 1     1     1     
Urban Rural 
    
   
  
  
      
Urban 187,191 46.8 1.003 0.975 1.031 1.019 0.991 1.048 .988 .951 1.026 
Accessible Remote 8,142 51.5 1.104 1.066 1.143 1.087 1.051 1.125 1.027 .980 1.076 
Very Remote 5,690 46.7 1     1     1     
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Table 2. Screening attendance proportions by SIMD and number of vaccine doses for women born between 1st January 1988-September 1993 
and invited for screening. 
Vaccine 
dose SIMD 
Total 
eligible Attended 
% 
uptake 
0 1 29983 13168 43.9 
  2 26815 11945 44.5 
  3 24548 10791 44 
  4 20796 9598 46.2 
  5 26487 10562 39.9 
1 1 1106 483 43.7 
  2 811 337 41.6 
  3 584 276 47.3 
  4 440 187 42.5 
  5 344 163 47.4 
2 1 1908 914 47.9 
  2 1478 696 47.1 
  3 1187 590 49.7 
  4 944 456 48.3 
  5 826 396 47.9 
3 1 12010 6338 52.8 
  2 12551 6853 54.6 
  3 12650 6862 54.2 
  4 12063 6559 54.4 
  5 13492 7286 54 
    201023 94460 47.6 
 
 
 Figure 1:  The proportion of women aged 20 attending for first screen within 12 months by 
year of birth and number of doses of vaccine.  Note those born prior to 1990 were not eligible 
for HPV vaccination. 
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Figure 2:  The proportion of unvaccinated women aged 20 attending for first screen within 12 
months by year of birth and SIMD.  Note those born prior to 1990 were not eligible for 
routine HPV vaccination and the whole cohort is represented here.  In the post-1990 cohorts, 
vaccine was offered and unvaccinated women chose not to receive the vaccine. 
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 Figure 3:  The proportion of vaccinated women aged 20 attending for first screen within 12 
months by year of birth and SIMD.  Vaccine was only offered to those born in 1990 or later 
and women chose to receive 1, 2 or 3 doses of the vaccine. 
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